In order not to go "off topic" in other post, I open this one with a general discution.
one small preview of the market condition:
"We estimate the global Hepatitis B (Hepatitis B) therapeutics market to be valued at $1.3bn in 2009. The market is estimated to grow up to $1.5bn in 2017, with a compound annual growth rate (CAGR) of 1.3%. This slow growth is attributed to the patent expiry of Baraclude in 2015. Growth in the Hepatitis B market will be driven by the increase in the number of patients. The US is the largest market for Hepatitis B and it contributes to approximately 50% of the global market"
And a list with big players:
" Analysis of the current and future market competition in the global Hepatitis B therapeutics market. The key future market players covered are Novartis, Gilead Sciences, Bristol Meyers Squibb, Hoffmann-La Roche Inc., Cytheris SA, LG Life Sciences Ltd, Enzo Biochem, Digna Biotech, Daewoong Pharma and IRX Therapeutics"
quote are from: http://www.informationbible.com/article-aarkstore-enterprise--hepatitis-b--pipeline-assessment-and-market-forecasts-to-2017-51853.html
Did anybody has the complete report: "Hepatitis B - Pipeline Review, Q1 2011 " or "Aarkstore Enterprise Hepatitis B Pipeline Assessment And Market Forecasts To 2017" ?